Skip to main content
. 2022 Nov 17;44(3):1129–1146. doi: 10.1002/hbm.26146

TABLE 1.

Demographic information and neuropsychological assessments

ADNI cohort Xuanwu cohort
Training data set Application data set Validation data set for SSIM Validation data set for dissimilarity
NC1 AD MCI NC2 NC3 aMCI naMCI NC4
N 412 292 309 300 105 35 35 35
Age (years) 72.47 ± 6.06 72.96 ± 6.92 73.40 ± 7.36 71.79 ± 5.46 65.61 ± 5.53*** 66.97 ± 7.63 64.89 ± 7.51 65.46 ± 4.94
Sex (F/M) 228/184 150/142 137/172 && 171/129 69/36 19/16 24/11 20/15
Education (years) 16.55 ± 2.52 15.35 ± 2.86 ### 16.17 ± 2.71 16.43 ± 2.38 12.29 ± 3.12*** 10.11 ± 3.76 §§ 10.34 ± 3.31 †† 12.00 ± 2.68
MMSE 29.10 ± 1.10 21.15 ± 4.49 ### 26.13 ± 3.85 &&& 28.83 ± 1.61 / / / /
CDR‐SB 0.06 ± 0.21 5.44 ± 2.27 ### 2.68 ± 2.36 &&& 0.25 ± 1.07 / / / /
AVLT‐(long) D / / / / 8.22 ± 2.56 2.46 ± 2.10 §§§ 4.69 ± 2.30 ††† 7.74 ± 2.07
AVLT‐Recognition / / / / 20.47 ± 4.61 7.53 ± 4.77 §§§ 19.86 ± 3.01 22.83 ± 1.13
MoCA‐B / / / / 25.63 ± 3.04 18.6 ± 4.27 §§§ 20.77 ± 3.99 ††† 26.46 ± 2.03
APOE ε4 124 (30.09%) 134 (45.89%) ### 126 (40.78%) && 100 (33.33%) 32 (30.48%%) 15 (42.86%) 13 (37.14%) 7 (20.00%)
Aβ42 in CSF (Aβ+/Aβ−) 24/53 73/14 45/21 24/12 / / / /
Follow‐up period for MCI (months) / / 32.14 ± 29.54 / / / / /
Converter rate of MCI / / 41 (18.72%) / / / / /

Abbreviations: AD, Alzheimer's disease; aMCI, amnestic MCI; APOE, apolipoprotein E; AVLT, Auditory Verbal Learning Test; Aβ, amyloid β; CDR‐SB, Clinical Dementia Rating‐Sum of Boxes; CSF, cerebral spinal fluid; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; naMCI, non‐aMCI; NC, normal control.

***

p < .001, comparison between NC1 and NC3.

###

p < .001, comparison between NC1 and AD.

&&

p < .01.

&&&

p < .001, comparison between NC1 and MCI.

§§

p < .01.

§§§

p < .01, comparison between NC3 and aMCI.

††

p < .01.

†††

p < .001, comparison between NC3 and naMCI.